Akebia Therapeutics, Inc.
NASDAQ:AKBABiotechnology
+$0.01 today
- Market cap
- $113.54M
- Beta
- 0.25
- P/E (TTM)
- -13.3
- EPS (TTM)
- -$0.08
Volume 7.09M
Average 4.03M
AKBA Net Margin
Net income as a percentage of revenue, showing how much of each sales dollar becomes profit.
Akebia Therapeutics, Inc.NASDAQ: AKBA
Net Margin · Q1 FY2026 · quarter ended Mar 2026
Net margin narrows to -16.9%
Net margin was -16.9% in Q1 FY2026, down 27.6 pp from a year earlier. On a trailing-twelve-month basis it was -8.8%, up 15.7 pp year over year. Over 3 fiscal years it widened by 30.0 pp.
Context
- Net margin widened in 2 of the last 3 fiscal years.
- FY2025 was the highest level in the 4 fiscal years shown.
What to watch
Whether net margin reaches the consensus estimate from 4 analysts of -28.3% for the fiscal year ending Dec 2026, down from -2.3% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -16.9%+4.3 pp QoQ
- Last fiscal yearDec 2025
- -2.3%+41.1 pp YoY
- LTMMar 2026
- -8.8%+15.7 pp YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -27.6 pp | -18.1 pp | +9.5 pp |
| 1 year | +41.1 pp | -26.0 pp | -67.1 pp |
| 3 years | +30.0 pp | -54.8 pp | -84.7 pp |
| 5 years | -18.1 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -2.3%
- Year-over-year change
- +41.1pp
| Period | Period end | Net Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -2.3% | +41.1pp |
| FY2024 | 2024-12-31 | -43.3% | -16.7pp |
| FY2023 | 2023-12-31 | -26.7% | +5.5pp |
| FY2022 | 2022-12-31 | -32.2% | +101.0pp |
| FY2021 | 2021-12-31 | -133.3% | — |
Net Margin vs competitors
How AKBA compares with its peers on the latest reported figures
- AKBA's LTM Mar 2026 net margin of -8.8% is the 3rd highest of the 7 companies compared; the peer median is -150.9%.
- Its year-over-year change of +15.7 pp is the 4th highest of 6, against a peer median of +103.2 pp.
- Over three fiscal years its change of +30.0 pp compares with a peer median of +257.5 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 121.5% | +103.2 pp | +173.4 pp | |
| LTM Mar 2026 | 101.6% | +328.2 pp | +341.6 pp | |
| LTM Mar 2026 | -8.8% | +15.7 pp | +30.0 pp | |
| LTM Dec 2025 | -119.4% | — | — | |
| LTM Mar 2026 | -182.3% | +766943.8 pp | +3271.0 pp | |
| LTM Mar 2026 | -260.9% | -181.0 pp | -2303.6 pp | |
| LTM Mar 2026 | -324.8% | -283.7 pp | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding AKBA) | -150.9% | +103.2 pp | +257.5 pp | |
Competitors are the stored peer set for AKBA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 211.65M | 292.48M | 194.62M | 160.18M | 236.2M |
| Cost of Revenue | 81.49M | 22.5M | 74.15M | 63.18M | 39.46M |
| Gross Profit | 130.16M | 269.99M | 120.47M | 97M | 196.73M |
| Gross Margin | 61.5% | 92.3% | 61.9% | 60.6% | 83.3% |
| Research & Development | 147.85M | 165.99M | 63.08M | 37.65M | 62.36M |
| Selling, General & Admin | 174.14M | 138.6M | 100.23M | 106.55M | 107.48M |
| Operating Expenses | 394.66M | 350.77M | 166.73M | 147.48M | 173.24M |
| Depreciation & Amortization | 37.97M | 37.7M | 37.63M | 37.5M | 1.27M |
| EBITDA | (189.91M) | 3.06M | (8.27M) | (13.72M) | 21.73M |
| EBITDA Margin | -89.7% | 1.0% | -4.2% | -8.6% | 9.2% |
| Operating Income | (264.5M) | (80.78M) | (46.26M) | (50.47M) | 23.5M |
| Operating Margin | -125.0% | -27.6% | -23.8% | -31.5% | 9.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 19.94M | 15.69M | 6.03M | 18.19M | 24.18M |
| Other Income / Expenses | (17.52M) | (13.45M) | (5.67M) | (18.94M) | (27.22M) |
| Income Before Tax | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (3.72M) |
| Pre-Tax Margin | -133.3% | -32.2% | -26.7% | -43.3% | -1.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 1.62M |
| Net Income | (282.02M) | (94.23M) | (51.93M) | (69.41M) | (5.35M) |
| Net Margin | -133.3% | -32.2% | -26.7% | -43.3% | -2.3% |
| EPS (Basic) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| EPS (Diluted) | (1.48) | (0.58) | (0.28) | (0.33) | (0.02) |
| Weighted Avg Shares | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
| Weighted Avg Shares (Diluted) | 165.95M | 182.78M | 187.47M | 210.95M | 257.16M |
Akebia Therapeutics, Inc.
NASDAQ:AKBA
Intrinsic Alpha fair value
Locked
Current Price
$0.41
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.